Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 396 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Immunodeficiency Disease Clear all
Completed Phase 1 Interventional

Interleukin-2 Treatment for Wiskott-Aldrich Syndrome

NCT00774358
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome (WAS), X-linked Thrombocytopenia
Interventions
Interleukin-2
Drug
Lead sponsor
Soma Jyonouchi
Other
Eligibility
24 Months and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 2, 2026, 3:20 AM EDT
Recruiting No phase listed Observational

Genetic Analysis of Immune Disorders

NCT00001467
View directory record Official record
Conditions
DOK 8, STAT1, GATA2, Immunodeficiency, STAT3
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 101 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 3:20 AM EDT
Terminated Not applicable Interventional

Targeting Non-virally Suppressed Adults With Alcohol Use Disorder in HIV Primary Care

NCT04280068
View directory record Official record
Conditions
Alcohol Dependence, HIV/AIDS
Interventions
Clinician Guide (CG), Clinician Guide plus HealthCall
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of a Telenovela/Soap Opera for HIV Prevention in Latinas

NCT05929482
View directory record Official record
Conditions
HIV Infections
Interventions
Infección de Amor (Infectious Love)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

NCT03277313
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years to 15 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Hartford, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 2, 2026, 3:20 AM EDT
Completed No phase listed Observational

Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990

NCT02064933
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Male only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Phase 3 Interventional Results available

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

NCT05819775
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 11 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 2, 2026, 3:20 AM EDT
Not listed Not applicable Interventional

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

NCT06276036
View directory record Official record
Conditions
Cytopenia
Interventions
Identification of specific markers
Other
Lead sponsor
Meyer Children's Hospital IRCCS
Other
Eligibility
1 Year to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 2, 2026, 3:20 AM EDT
Completed No phase listed Observational Results available

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

NCT01059526
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
40
States / cities
Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 2, 2026, 3:20 AM EDT
Terminated Phase 4 Interventional

Antibody Production in Immune Disorders

NCT00023504
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Pneumovax, Rabavert, Prevnar, Tetanus diphtheria toxoid
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 2, 2026, 3:20 AM EDT
Enrolling by invitation No phase listed Observational

Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies

NCT06144229
View directory record Official record
Conditions
Hiv, Hpv
Interventions
Self-Collection HPV testing kit from Abbott
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 2, 2026, 3:20 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus

NCT04370795
View directory record Official record
Conditions
Severe Combined Immune Deficiency (SCID)
Interventions
Sirolimus, Busulfan, Horse -Anti-thymocyte, G-CSF, Total Body Irradiation (TBI)
Drug · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Motiv82Change: an HIV Prevention Study for Young Latino Men

NCT00877695
View directory record Official record
Conditions
HIV Infections
Interventions
Entre Culturas: Navigating Culture, Identity, and HIV Risk
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Not applicable Interventional Results available

Feasibility of SBIRT-PN

NCT03057119
View directory record Official record
Conditions
Substance Use, HIV/AIDS, Older Adults, Behavioral Intervention, Infectious Disease
Interventions
Psycho-educational content (5 Minutes), Readiness Assessment (10 minutes), Goal-Setting (5 minutes), Identifying and prioritizing needs (5 minutes), Explanation of Peer Navigator and Session wrap (5 minutes)
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida • Lake City, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Phase 3 Interventional Results available

Study of PlasmaCap IG in Adults and Children With PIDD

NCT03238079
View directory record Official record
Conditions
Primary Immune Deficiency Diseases (PIDD)
Interventions
10% IGIV
Biological
Lead sponsor
Evolve Biologics
Industry
Eligibility
2 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Centennial, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 2, 2026, 3:20 AM EDT
Completed No phase listed Observational

Biological Significance of the Bloom's Syndrome Protein

NCT00021437
View directory record Official record
Conditions
Bloom Syndrome
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
2 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Phase 2 Interventional

Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency

NCT00031005
View directory record Official record
Conditions
Leukocyte-Adhesion Deficiency Syndrome
Interventions
modified stem cell transplant
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 3:20 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
16
States / cities
Paradise Valley, Arizona • La Jolla, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 2, 2026, 3:20 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

NCT01176006
View directory record Official record
Conditions
DOCK8 Deficiency
Interventions
Reduced-intensity hematopoietic stem cell, Fludarabine(Fludara, Berlex Laboratories), Cyclophosphamide(CTX, Cytoxan), Total Body Irradiation (TBI), Busulfan (Busulfex), Donor peripheral blood stem cell mobiliation and collection, Bone Marrow Harvest Procedure
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

NCT00157079
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 2, 2026, 3:20 AM EDT
Completed No phase listed Observational

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

NCT02593188
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
16 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
30
States / cities
Bakersfield, California • Irvine, California • Redondo Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 2, 2026, 3:20 AM EDT
Recruiting Phase 3 Interventional

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480
View directory record Official record
Conditions
Multiple Myeloma, Secondary Immunodeficiency
Interventions
IGI, 10%
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men

NCT02572401
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Sexually Transmitted Disease (STD)
Interventions
STAND HIV Risk Reduction Intervention, Text Messaging Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
391 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 2, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

NCT03712228
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Factor XIIa antagonist monoclonal antibody, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 2, 2026, 3:20 AM EDT